Onconetix (ONCO) investor relations material

Executive summary

• Focused on oncology solutions, with Proclarix as the main commercial product after discontinuing ENTADFI and vaccine programs.

• Q1 2026 operational progress included clinical and commercial milestones for Proclarix, with new peer-reviewed publications supporting its clinical utility.

• Initiated the PRIME multi-center clinical validation study in the U.S. with Labcorp and expanded commercial presence in Europe, including the UK and Turkey.

• Entered a Share Exchange Agreement to acquire Realbotix, subject to significant closing conditions and financing.

• Recent financings (Series D and E) provided short-term liquidity, but substantial doubt remains about the ability to continue as a going concern.

Financial highlights

• Revenue for Q1 2026 was $21,457, down 79% year-over-year; gross loss of $1,655 due to low sales and fixed costs.

• Net loss for Q1 2026 was $4.2 million, a 51% improvement from Q1 2025's $8.5 million loss, mainly due to lower impairment charges.

• Cash as of March 31, 2026 was $3.7 million, with a working capital surplus of $1.3 million and an accumulated deficit of $135.4 million.

• Operating cash outflow for Q1 2026 was $2.1 million.

• Series D and E PIPE financings in late 2025 raised $15.5 million gross, supporting near-term operations.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for the foreseeable future.

• Additional capital is required to fund operations, commercialize Proclarix, and close the Realbotix transaction.

• Anticipates marketing Proclarix in the U.S. as a lab developed test through a license agreement with Labcorp.

• Ongoing efforts to expand market reach into additional European countries.

• If unable to secure funding, may need to curtail development, commercialization, or file for bankruptcy.